To compare hemorrhagic morbidity among pregnancies affected by invasive placentation with and without co-existing placenta previa STUDY DESIGN: We conducted a retrospective cohort study of deliveries at a tertiary care center from 1997 to 2017 with histologically-confirmed invasive placentation. The primary outcome was transfusion of any blood product; secondary outcomes were transfusion of specific blood products, estimated blood loss, number of units transfused and intensive care unit admission. Risk ratios (RR) and 95% confidence intervals (CI) are reported.
OBJECTIVE:
To compare hemorrhagic morbidity among pregnancies affected by invasive placentation with and without co-existing placenta previa STUDY DESIGN: We conducted a retrospective cohort study of deliveries at a tertiary care center from 1997 to 2017 with histologically-confirmed invasive placentation. The primary outcome was transfusion of any blood product; secondary outcomes were transfusion of specific blood products, estimated blood loss, number of units transfused and intensive care unit admission. Risk ratios (RR) and 95% confidence intervals (CI) are reported.
RESULTS:
We identified 105 pregnancies complicated by invasive placentation, 47 with previa and 58 without. Women with previa were more likely to have an antenatal diagnosis of invasive placentation, a greater depth of invasion and to deliver at an earlier gestational age (all p<0.001). After adjusting for depth of invasion, women with pregnancies complicated by previa were more likely to receive a blood transfusion compared to those without (RR: 2.0; 95% CI: 1.3-3.1). Women with previa were more likely to receive packed red blood cells, platelets and cryoprecipitate, but not fresh frozen plasma or cell saver (Table 1) . Compared to deliveries among women without previa, those with previa were complicated by larger median estimated blood loss and more units of packed red blood cells transfused (both p0.03), though the number of units of fresh frozen plasma and cryoprecipitate were similar (both p0.53). Women with previa were more likely to have a hysterectomy (crude RR 2.7; 95% CI: 1.8-3.8) and be admitted to the intensive care unit (RR: 3.3; 95% CI: 1.1-9.6, adjusted for depth of invasion). CONCLUSION: Among pregnancies complicated by invasive placentation, those with co-existing placenta previa experienced greater hemorrhagic morbidity as compared to those without. Given the increased morbidity, pregnancies complicated by both invasive placentation and placenta previa warrant multi-disciplinary preoperative planning and care.
369 Optimal timing of cesarean hysterectomy for women with placenta accreta spectrum Rosa J. Speranza, Kimberley A. Bullard, James A. Sargent, Aaron B. Caughey
Oregon Health & Science University, Portland, OR OBJECTIVE: The incidence of placenta accreta has increased dramatically in the last several decades. Scheduled cesarean hysterectomy at a multidisciplinary care facility has been shown to improve outcomes, however the ideal timing of delivery remains uncertain based on limited analyses. We sought to determine the optimal gestational week to schedule a cesarean hysterectomy among women with suspected placenta accreta spectrum. STUDY DESIGN: A decision analytic model was created using TreeAgePro software to compared outcomes of scheduled cesarean hysterectomy between 32 and 37 weeks of gestation. We calculated the rate of spontaneous delivery, antepartum hemorrhage requiring emergent cesarean hysterectomy and the risk of intrauterine fetal demise (IUFD) during the period of expectant management for each advancing week. Access to a multidisciplinary team at tertiary care facilities was incorporated into the model. Only scheduled deliveries were assumed to have adequate time to administer antenatal corticosteroids, and we calculated reduced rates of respiratory distress Poster Session II ajog.org syndrome (RDS), cerebral palsy and neonatal death upon steroid administration. All probabilities and utilities were derived from the literature. Neonatal outcomes included IUFD, RDS, cerebral palsy, and neonatal death. Maternal outcomes included maternal death and rates of severe hemorrhage defined as bleeding requiring greater than 10 units of blood products. RESULTS: In a theoretical cohort of 10,000 women with placenta accreta, scheduled cesarean hysterectomy at 35 weeks of gestation with corticosteroid administration optimized maternal and neonatal outcomes (table) . Delivery at 32 weeks resulted in the fewest maternal deaths (298) and incidents of severe hemorrhage (194) . Neonatal outcomes except for IUFD were optimized with delivery at 37 weeks of gestation and included 23 cases of neonatal death, 55 cases of cerebral palsy, and 482 cases of RDS. CONCLUSION: Based on our analysis, optimal management for placenta accreta spectrum is a scheduled cesarean hysterectomy at 35 weeks gestation in a multidisciplinary care center with prior corticosteroid administration. Further efforts to identify those patients at risk of requiring an emergent delivery would help to further optimize maternal and neonatal outcomes. OBJECTIVE: To validate the accuracy of an external device which monitors uterine electrical activity by comparing it to tocodynamometry among obese patients. STUDY DESIGN: This was a prospective observational study of laboring women at Montefiore Medical Center from February 2017 to April 2018. Inclusion criteria: maternal age >18 years old, singleton pregnancy, gestational age > 24 weeks and BMI >/¼ 30 kg/m2. Exclusion criteria: allergy to silver, implanted electronic device of any kind and irritated skin or open wound on the abdominal wall. Patients were monitored simultaneously with the EUM device, EUM300 (OB Tools, Migdal HaEmek, Israel), and by TOCO for at least 30 minutes. Two blinded obstetricians reviewed the tracings. The primary outcome of the study was continuous, interpretable tracing and secondary outcomes were total number of contractions, timing of onset of contractions and duration of contractions. Based on McNemar's test to compare proportion of discontinuity between the two methods, enrolling 55 patients provided 80% study power to detect an odds ratio of 3.2 with a two-sided type I error rate of 5%. RESULTS: A total of 65 obese patients were monitored via simultaneous EUM and TOCO devices. The average gestational age was 39.0 weeks with 43 (66.15%) patients in latent labor. 35 (53.85%) patients were receiving oxytocin at the time of the recordings and 45
